Citi maintains a neutral rating on GSK shares despite promising clinical trial results for its hepatitis B drug, bepirovirsen, which showed a functional cure in up to 26% of patients. The cautious stance is due to unresolved commercial issues such as drug pricing, initial market access, and the practicality of required monitoring in real-world settings. Bepirovirsen offers a new treatment approach by silencing the virus's replication instructions, potentially improving on current therapies that rarely cure the disease. Hepatitis B affects around 300 million people globally, and Citi forecasts peak annual sales of £1.6 billion for the drug, aligning with market expectations.
UBS maintains a neutral rating on GSK ahead of its Q2 results, focusing on CEO Luke Miels' upcoming strategy update. UBS expects little market reaction to the earnings, highlighting concerns over a £4 billion gap between GSK's sales target and foreca...
UBS maintains a neutral rating on GSK ahead of its Q2 results and a strategy update from new CEO Luke Miels, focusing on whether he can deliver GSK's target of over £40 billion in risk-adjusted sales by 2031. UBS forecasts slightly below consensus fo...
